Abstract
Oxaliplatin (trans-/-diaminocyclohexane oxalatoplatinum; L-OHP) is a new platinum derivative for the treatment of advanced colorectal cancer. Preclinical data have shown that oxaliplatin is active in a wide range of human and murine tumour cell lines, and has been found to be non-cross-resistant with cisplatin in various cisplatin-resistant cell lines and tumours. Oxaliplatin in combination with 5-fluorouracil (5-FU) leads to synergistic antiproliferative activity both in vivo and in vitro. Clinical data have shown that oxaliplatin is active and well tolerated both as monotherapy and in combination with 5-FU/folinic acid in first- or second-line treatment of patients with metastatic colorectal cancer. Oxaliplatin has a very good safety profile, and studies have confirmed that peripheral sensory neuropathy is related to the cumulative dose of oxaliplatin administered and that this neuropathy is generally reversible after discontinuation of treatment. High response rates and prolonged survival have been achieved in metastatic colorectal cancer patients, even after 5-FU failure.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bleiberg, H. Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 77 (Suppl 4), 1–3 (1998). https://doi.org/10.1038/bjc.1998.427
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.427
This article is cited by
-
The advancing of polymeric core–shell ZnO nanocomposites containing 5-fluorouracil for improving anticancer activity in colorectal cancer
Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
-
Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents
Journal of the Association for Research in Otolaryngology (2020)
-
Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer
Cell Death & Disease (2019)
-
Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models
British Journal of Cancer (2014)
-
A multicenter randomized phase II trail of Oxaliplatin in the patients with colorectal cancer
The Chinese-German Journal of Clinical Oncology (2008)